1,2-Dichloroethane → 2',4'-Difluoro-5-piperazin-1-yl-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}biphenyl-3-carboxamide

HRID 888389노트

반응식

HRID 888389 반응식
C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[CH:15]=[C:16]([C:28]([OH:30])=O)[CH:17]=[C:18]([C:20]3[CH:25]=[CH:24][C:23]([F:26])=[CH:22][C:21]=3[F:27])[CH:19]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.Cl.Cl.[F:33][C:34]([F:45])([F:44])[C:35]1[N:40]=[CH:39][C:38]([C@H:41]([NH2:43])[CH3:42])=[CH:37][N:36]=1.C(Cl)CCl.C1C=CC2N(O)N=NC=2C=1.C(N(C(C)C)CC)(C)C.Cl>CN(C)C=O>[F:27][C:21]1[CH:22]=[C:23]([F:26])[CH:24]=[CH:25][C:20]=1[C:18]1[CH:19]=[C:14]([N:11]2[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]2)[CH:15]=[C:16]([C:28]([NH:43][C@@H:41]([C:38]2[CH:37]=[N:36][C:35]([C:34]([F:45])([F:44])[F:33])=[N:40][CH:39]=2)[CH3:42])=[O:30])[CH:17]=1

참가 물질

8

실험 절차

To a solution of 5-[4-(tert-butoxycarbonyl)piperazin-1-yl]-2′,4′-difluorobiphenyl-3-carboxylic acid (30.0 mg, 0.072 mmol), in N,N-dimethylformamide (1.0 mL) was added (1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethanamine dihydrochloride (22.7 mg, 0.086 mmol), EDC (17.8 mg, 0.093 mmol), HOBT (11.0 mg, 0.072 mmol) and diisopropylethylamine (0.038 mL, 0.215 mmol). After 16 h, the mixture was acidified with hydrochloric acid gas. After 15 min, the mixture was concentrated and purified by reverse phase HPLC (C-18, 95% water/acetonitrile→25% water/acetonitrile with 0.1% trifluoroacetic acid) to give the title compound (28.4 mg). HRMS 492.1833 (M+1). 1H NMR (500 MHz, CD3OD): δ 9.00 (s, 2H); 7.57-7.50 (m, 1H); 7.47-7.43 (m, 2H); 7.24 (q, J=1.7 Hz, 1H); 7.09-7.03 (m, 2H); 5.33 (q, J=7.1 Hz, 1H); 3.25 (t, J=4.9 Hz, 4H); 3.00 (t, J=4.7 Hz, 4H); 1.68 (d, J=7.2 Hz, 3H).

후처리

  1. waitAfter 15 min
  2. concentrationthe mixture was concentrated
  3. custompurified by reverse phase HPLC (C-18, 95% water/acetonitrile→25% water/acetonitrile with 0.1% trifluoroacetic acid)

출처 및 근거

ORD 기록
ord-6ee96bed8d394fe88d76d173f770c92a
출처 데이터셋
uspto-grants-2012_08
특허 번호
US08247401B2

반응 노트

불러오는 중…